<code id='214D8DE2C8'></code><style id='214D8DE2C8'></style>
    • <acronym id='214D8DE2C8'></acronym>
      <center id='214D8DE2C8'><center id='214D8DE2C8'><tfoot id='214D8DE2C8'></tfoot></center><abbr id='214D8DE2C8'><dir id='214D8DE2C8'><tfoot id='214D8DE2C8'></tfoot><noframes id='214D8DE2C8'>

    • <optgroup id='214D8DE2C8'><strike id='214D8DE2C8'><sup id='214D8DE2C8'></sup></strike><code id='214D8DE2C8'></code></optgroup>
        1. <b id='214D8DE2C8'><label id='214D8DE2C8'><select id='214D8DE2C8'><dt id='214D8DE2C8'><span id='214D8DE2C8'></span></dt></select></label></b><u id='214D8DE2C8'></u>
          <i id='214D8DE2C8'><strike id='214D8DE2C8'><tt id='214D8DE2C8'><pre id='214D8DE2C8'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:comprehensive    Page View:8663
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In